Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Felipe Marques Gonçalves
Observed names:
F. Marques Goncalves,
Felipe Marques Goncalves,
Goncalves, Felipe Marques
Institution:
Genmab (United States)
Observed institution:
Genmab (United States)
OpenAlex ID:
A5115008236
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
2025
·
Alexey V. Danilov
, Swetha Kambhampati Thiruvengadam
, et al.
·
Blood Advances
·
10
PDF
POSTER: IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND
2026
·
Kim M Linton
, Moshe Yair Levy
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND
2026
·
Kim M Linton
, Moshe Yair Levy
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
IBCL-770: Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma
2025
·
Julie M. Vose
, Paolo F. Caimi
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-770 Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second-Line or Later Follicular Lymphoma
2025
·
Julie M. Vose
, Paolo F. Caimi
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma
2025
·
Zhijie Ding
, Guihua Zhang
, et al.
·
Future Oncology
PDF
241 | Matching‐adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Tafasitamab With Rituximab + Lenalidomide in Second‐line + Follicular Lymphoma
2025
·
J. M. Vose
, P. F. Caimi
, et al.
·
Hematological Oncology
PDF
248 | Matching‐adjusted Indirect Comparison of Epcoritamab With Rituximab + Lenalidomide Versus Lisocabtagene Maraleucel in Second‐line Follicular Lymphoma
2025
·
J. Villasboas
, K. Yang
, et al.
·
Hematological Oncology
PDF
Matching-Adjusted Indirect Treatment Comparison of Epcoritamab Versus Zanubrutinib Plus Obinutuzumab in Relapsed or Refractory Follicular Lymphoma
2024
·
Karen Cumings
, Viktor Chirikov
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
10
Citation count:
10
H-index:
1
I10-index:
1
Year
Topic
Type
